NCT07116889Active, not recruitingPhase 1
A Phase 1 Study to Investigate the Safety and Tolerability of the Study Drug GB-0895 in Mild to Moderate Asthma Patients or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Sept 2026
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (estimated)
- First submitted
- 14 Nov 2023
- Start date
- 1 Mar 2024
- Lead sponsor
- Generate Biomedicines Inc.
- EU CT number
- 2023-507611-35-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 70
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Research Organisation GmbH Coordinator of this site? Confirm its status | Berlin | Germany | Active, not recruiting |
| IKF Pneumologie GmbH & Co. KG Coordinator of this site? Confirm its status | Frankfurt am Main | Germany | Active, not recruiting |
| The Fraunhofer Institute For Toxicology And Experimental Medicine ITEM Coordinator of this site? Confirm its status | Hanover | Germany | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.